Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Income from Continuing Operations (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Income from Continuing Operations data on record, last reported at 39685000.0 in Q4 2023.

  • For Q4 2023, Income from Continuing Operations fell 46.73% year-over-year to 39685000.0; the TTM value through Dec 2023 reached 169223000.0, down 294.18%, while the annual FY2025 figure was 219879000.0, 31.21% down from the prior year.
  • Income from Continuing Operations reached 39685000.0 in Q4 2023 per CGEM's latest filing, down from 39183000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 174065000.0 in Q2 2022 and bottomed at 58141000.0 in Q1 2023.
  • Average Income from Continuing Operations over 4 years is 13063062.5, with a median of 27229500.0 recorded in 2022.
  • The widest YoY moves for Income from Continuing Operations: up 1158.85% in 2022, down 2387.53% in 2022.
  • A 4-year view of Income from Continuing Operations shows it stood at 29094000.0 in 2020, then decreased by 17.57% to 34206000.0 in 2021, then rose by 20.93% to 27046000.0 in 2022, then tumbled by 46.73% to 39685000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 39685000.0 in Q4 2023, 39183000.0 in Q3 2023, and 32214000.0 in Q2 2023.